During the last session, Inovio Pharmaceuticals Inc (NASDAQ:INO)’s traded shares were 0.47 million, with the beta value of the company hitting 0.90. At the end of the trading day, the stock’s price was $8.44, reflecting an intraday loss of -3.10% or -$0.27. The 52-week high for the INO share is $14.75, that puts it down -74.76 from that peak though still a striking 53.91% gain since the share price plummeted to a 52-week low of $3.89. The company’s market capitalization is $218.68M, and the average intraday trading volume over the past 10 days was 0.28 million shares, and the average trade volume was 378.67K shares over the past three months.
Inovio Pharmaceuticals Inc (INO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. INO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.08.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
Inovio Pharmaceuticals Inc (INO) registered a -3.10% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.10% in intraday trading to $8.44, hitting a weekly high. The stock’s 5-day price performance is -11.06%, and it has moved by -23.55% in 30 days. Based on these gigs, the overall price performance for the year is 74.14%. The short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) is 2.8 million shares and it means that shorts have 5.12 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 57.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $40 respectively. As a result, INO is trading at a discount of -373.93% off the target high and 5.21% off the low.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
Statistics show that Inovio Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Inovio Pharmaceuticals Inc (INO) shares have gone up 47.04% during the last six months, with a year-to-date growth rate more than the industry average at 26.11% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 30.80% this quarter and then jump 11.60% in the quarter after that. In the rating firms’ projections, revenue will decrease -57.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 120k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 120k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 388k and 103k respectively. In this case, analysts expect current quarter sales to shrink by -69.10% and then jump by 16.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 13.49%. While earnings are projected to return 25.31% in 2024, the next five years will return 41.50% per annum.
INO Dividends
Inovio Pharmaceuticals Inc is due to release its next quarterly earnings 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Inovio Pharmaceuticals Inc insiders own 0.84% of total outstanding shares while institutional holders control 18.27%, with the float percentage being 18.42%. PRIME CAPITAL INVESTMENT ADVISORS, LLC is the largest shareholder of the company, while 116.0 institutions own stock in it. As of 2024-03-31, the company held over 10172.0 shares (or 0.0459% of all shares), a total value of $0.14 million in shares.
The next largest institutional holding, with 175.0 shares, is of IFP ADVISORS, INC’s that is approximately 0.0008% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $2429.0.
Also, the Mutual Funds coming in first place with the largest holdings of Inovio Pharmaceuticals Inc (INO) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 714.47 shares. This amounts to just over 2.76 percent of the company’s overall shares, with a $6.03 million market value. The same data shows that the other fund manager holds slightly less at 603.43, or about 2.33% of the stock, which is worth about $5.09 million.
